⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852880 | 1.00 | — | — | |
| SCHEMBL5666186 | 1.00 | — | — | |
| SCHEMBL1253601 | 0.81 | CTH (0.47) | — | |
| SCHEMBL9876478 | 0.77 | — | — | |
| SCHEMBL17716524 | 0.77 | — | — | |
| SCHEMBL4250439 | 0.76 | CTH (0.44) | — | |
| SCHEMBL4250435 | 0.76 | CTH (0.44) | — | |
| SCHEMBL214327 | 0.72 | CTH (0.45) | — | |
| SCHEMBL214326 | 0.72 | CTH (0.45) | — | |
| SCHEMBL15871027 | 0.72 | RAB9A (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030215929-A1 | Rhodococcus gene encoding aldoxime dehydratase | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-11-20 | — | — | US | claimed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116568310-A | Boric acid compounds | 株式会社LG化学 | 2023-08-08 | — | — | CN | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200261450-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| US-10668065-B2 | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-02 | — | — | US | disclosed |
| US-20190160061-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-30 | — | — | US | disclosed |
| US-10220032-B2 | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-05 | — | — | US | disclosed |
| US-20170273976-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-28 | — | — | US | disclosed |
| US-20170273976-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-28 | — | — | US | disclosed |
| US-8383658-B2 | Isoxazole based neuronal nicotinic receptor ligands and methods of use | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2009149135-A1 | BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090306096-A1 | Novel Isoxazoles and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | US | disclosed |
| US-7579349-B2 | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| EP-1678169-B1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| EP-1678169-A1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| US-7057030-B2 | Rhodococcus gene encoding aldoxime dehydratase | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
| US-20030215929-A1 | Rhodococcus gene encoding aldoxime dehydratase | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-11-20 | — | — | US | disclosed |